BOSTON — Boston medical researchers are hoping to get ahead of Alzheimer’s by testing a possible treatment in patients who don’t have symptoms but may be at risk for the progressive disease.
Brigham and Women’s Hospital is part of the global AHEAD Study, an Alzheimer’s clinical trial that is looking at whether an investigational treatment can slow or stop the earliest brain changes in people with a higher risk of developing the disease later in life.
The scientists, who are seeking participants for the four-year clinical trial, are testing lecanemab — the recently FDA-approved Biogen drug for patients exhibiting Alzheimer’s symptoms — in patients as young as 55 years old who are at risk of developing symptoms as they get older.
